Literature DB >> 3128510

Heparin inhibits infectivity of human immunodeficiency virus in vitro.

T Nagumo1, H Hoshino.   

Abstract

The infectivity of human immunodeficiency virus (HIV) was inhibited by heparin, though de-N-sulfated heparin and heparin pretreated with protamine sulfate were hardly inhibitory. There was a correlation between the anticoagulant activities and anti-HIV activities of heparin-related compounds.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3128510      PMCID： PMC5907755          DOI： 10.1111/j.1349-7006.1988.tb00003.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


  8 in total

1.  Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine.

Authors:  R Ueno; S Kuno
Journal:  Lancet       Date:  1987-06-13       Impact factor: 79.321

Review 2.  Strategies for antiviral therapy in AIDS.

Authors:  H Mitsuya; S Broder
Journal:  Nature       Date:  1987 Feb 26-Mar 4       Impact factor: 49.962

Review 3.  Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).

Authors:  E De Clercq
Journal:  J Med Chem       Date:  1986-09       Impact factor: 7.446

4.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

5.  Isolation of human immunodeficiency virus from a Japanese hemophilia B patient with AIDS.

Authors:  Y Takeuchi; M Inagaki; N Kobayashi; H Hoshino
Journal:  Jpn J Cancer Res       Date:  1987-01

6.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

7.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

8.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728
  8 in total
  3 in total

1.  Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses.

Authors:  Cathrine Scheepers; Sudipa Chowdhury; W Shea Wright; Christopher T Campbell; Nigel J Garrett; Quarraisha Abdool Karim; Salim S Abdool Karim; Penny L Moore; Jeffrey C Gildersleeve; Lynn Morris
Journal:  AIDS       Date:  2017-10-23       Impact factor: 4.177

2.  Identification and mapping of functional domains on human T-cell lymphotropic virus type 1 envelope proteins by using synthetic peptides.

Authors:  Y Sagara; Y Inoue; H Shiraki; A Jinno; H Hoshino; Y Maeda
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

Review 3.  Sulfated Glycans and Related Digestive Enzymes in the Zika Virus Infectivity: Potential Mechanisms of Virus-Host Interaction and Perspectives in Drug Discovery.

Authors:  Vitor H Pomin
Journal:  Interdiscip Perspect Infect Dis       Date:  2017-01-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.